Small molecule · Inhibitor of Hematopoietic prostaglandin D synthase (HPGDS) · developed by Zai Lab Pty.
ZL-2102 is a selective and reversible inhibitor of hematopoietic prostaglandin D synthase (HPGDS). It is studied in chronic obstructive pulmonary disease, asthma, and idiopathic pulmonary fibrosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02397005 | Phase 1 | Chronic Obstructive Pulmonary Disease | Unknown | ZLAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AsthmaChronic Obstructive Pulmonary DiseaseIdiopathic Pulmonary Fibrosis
Updated Nov 1, 2026. Something wrong or missing? Report it on the ZLAB page.
See ZLAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ZLAB catalysts and pipeline →